Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Baxter
Harvard Business School
AstraZeneca
Johnson and Johnson

Last Updated: June 27, 2022

CAMPATH Drug Profile


✉ Email this page to a colleague

« Back to Dashboard

Recent Clinical Trials for CAMPATH

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPhase 2
M.D. Anderson Cancer CenterPhase 1
National Cancer Institute (NCI)Phase 1

See all CAMPATH clinical trials

Recent Litigation for CAMPATH

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
AMGEN INC. v. APOTEX INC.2022-06-14
AbbVie Inc. v. Alvotech hf.2021-05-28
Alvotech USA Inc. v. Abbvie Inc2021-05-11

See all CAMPATH litigation

PTAB Litigation
PetitionerDate
Miltenyi Biomedicine GmbH2022-04-12
GEMoaB Monoclonals GmbH2019-12-20
Forty Seven, Inc.2018-01-08

See all CAMPATH litigation

Pharmacology for CAMPATH
Mechanism of ActionCD52-directed Antibody Interactions
Established Pharmacologic ClassCD52-directed Cytolytic Antibody
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for CAMPATH Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for CAMPATH Derived from Company Disclosures

These patents were obtained from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Patent No. Estimated Patent Expiration Source
Genzyme Corporation CAMPATH alemtuzumab Injection 103948 See Plans and Pricing 2013-08-13 Company disclosures
Genzyme Corporation CAMPATH alemtuzumab Injection 103948 See Plans and Pricing 2013-08-13 Company disclosures
Genzyme Corporation CAMPATH alemtuzumab Injection 103948 See Plans and Pricing 2014-08-05 Company disclosures
Genzyme Corporation CAMPATH alemtuzumab Injection 103948 See Plans and Pricing 2015-12-08 Company disclosures
Genzyme Corporation CAMPATH alemtuzumab Injection 103948 See Plans and Pricing 2013-12-28 Company disclosures
Genzyme Corporation CAMPATH alemtuzumab Injection 103948 See Plans and Pricing 2020-05-27 Company disclosures
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Patent No. >Estimated Patent Expiration >Source

3) Low Certainty: US Patents for CAMPATH Derived from Patent Text Search

These patents were obtained by searching patent claims

Supplementary Protection Certificates for CAMPATH

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
300067 Netherlands See Plans and Pricing PRODUCT NAME: ALEMTUZUMAB; REGISTRATION NO/DATE: EU/1/01/193/001 20010706
132016000055697 Italy See Plans and Pricing PRODUCT NAME: ALEMTUZUMAB(LEMTRADA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/13/869, 20130916
122016000041 Germany See Plans and Pricing PRODUCT NAME: ALEMTUZUMAB; REGISTRATION NO/DATE: EU/1/13/869 20130912
300816 Netherlands See Plans and Pricing PRODUCT NAME: ALEMTUZUMAB; REGISTRATION NO/DATE: EU/1/13/869 20130916
CA 2016 00026 Denmark See Plans and Pricing PRODUCT NAME: ALEMTUZUMAB; REG. NO/DATE: EU/1/13/869 20130916
C20160019 00200 Estonia See Plans and Pricing PRODUCT NAME: ALEMTUZUMAB;REG NO/DATE: EU/1/13/869 16.09.2013
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
Baxter
Express Scripts
Moodys
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.